Zhe Li1, Ben-Fillippo Krippendorff2, Dhaval K Shah3. 1. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, New York, 14214-8033, USA. 2. Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Quantitative Systems Pharmacology, Roche Innovation Center Basel, CH-4070, Basel, Switzerland. 3. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, Buffalo, New York, 14214-8033, USA. dshah4@buffalo.edu.
Abstract
PURPOSE: To establish a continuous relationship between the size of various antibody fragments and their systemic clearance (CL) in mice. METHODS: Two different orthogonal approaches have been used to establish the relationship. First approach uses CL values estimated by non-compartmental analysis (NCA) to establish a correlation with protein size. The second approach simultaneously characterizes the PK data for all the proteins using a 2-compartment model to establish a relationship between protein size and pharmacokinetic (PK) parameters. RESULTS: Simple mathematical functions (e.g. sigmoidal, power law) were able to characterize the CL vs. protein size relationship generated using the investigated proteins. The relationship established in mouse was used to predict rat, rabbit, monkey, and human relationships using allometric scaling. The predicted relationships were found to capture the available spares data from each species reasonably well. CONCLUSIONS: The CL vs. protein size relationship is important for establishing a robust quantitative structure-PK relationship (QSPKR) for protein therapeutics. The relationship presented here can help in a priori predicting plasma exposure of therapeutic proteins, and together with our previously established relationship between plasma and tissue concentrations of proteins, it can predict the tissue exposure of non-binding proteins simply based on molecular weight/radius and dose.
PURPOSE: To establish a continuous relationship between the size of various antibody fragments and their systemic clearance (CL) in mice. METHODS: Two different orthogonal approaches have been used to establish the relationship. First approach uses CL values estimated by non-compartmental analysis (NCA) to establish a correlation with protein size. The second approach simultaneously characterizes the PK data for all the proteins using a 2-compartment model to establish a relationship between protein size and pharmacokinetic (PK) parameters. RESULTS: Simple mathematical functions (e.g. sigmoidal, power law) were able to characterize the CL vs. protein size relationship generated using the investigated proteins. The relationship established in mouse was used to predict rat, rabbit, monkey, and human relationships using allometric scaling. The predicted relationships were found to capture the available spares data from each species reasonably well. CONCLUSIONS: The CL vs. protein size relationship is important for establishing a robust quantitative structure-PK relationship (QSPKR) for protein therapeutics. The relationship presented here can help in a priori predicting plasma exposure of therapeutic proteins, and together with our previously established relationship between plasma and tissue concentrations of proteins, it can predict the tissue exposure of non-binding proteins simply based on molecular weight/radius and dose.
Authors: A G Norden; M Lapsley; P J Lee; C D Pusey; S J Scheinman; F W Tam; R V Thakker; R J Unwin; O Wrong Journal: Kidney Int Date: 2001-11 Impact factor: 10.612
Authors: Donald E Mager; Mary A Mascelli; Neal S Kleiman; Desmond J Fitzgerald; Darrell R Abernethy Journal: J Pharmacol Exp Ther Date: 2003-10-08 Impact factor: 4.030
Authors: Peter Bloomingdale; Suruchi Bakshi; Christian Maass; Eline van Maanen; Cesar Pichardo-Almarza; Daniela Bumbaca Yadav; Piet van der Graaf; Nitin Mehrotra Journal: J Pharmacokinet Pharmacodyn Date: 2021-08-10 Impact factor: 2.745